A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Gastrointestinal Tract Cancer. According to GlobalData, Phase II drugs for Gastrointestinal Tract Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback